Fig. 6: CHOP-RNA Polymerase II association to IL-8 gene promoter.

LS180 cell line was treated with fixed doses of dabrafenib (D) and trametinib (T) for 8 h, as indicated. a Whole LS180 lysate was immunoprecipitated with either anti-CHOP antibodies or control IgG and analyzed by WB using specific antibodies, as indicated; WB of the whole cell lysate are reported as control. LS180 chromatin was immunoprecipitated with anti-CHOP (b), anti-RNA Polymerase II (c, d) or anti-Acetyl-Histone H4 (e) antibodies or with control IgG and analyzed by RT-qPCR with primers specific for CHOP-binding region and TATA box of the IL-8 gene promoter. Results of a representative experiment out of three independent experiments performed are shown. f Cell lines were co-transfected with 100 ng luc-reporter vector and 10 ng pRL-TK. Cells were harvested for luc assay 24 h post-transfection and treated with fixed doses of D and T for 24 h, as indicated. pXP2 empty vector plasmid was used as a control. Results of a representative experiment out of three independent experiments performed are shown.